Kota Semarang

This trial is for adults who have had an acute ischemic stroke caused by a blood clot blocking a brain vessel. It focuses on people whose stroke occurred or was discovered more than 4.5 hours ago, including those who woke up with stroke symptoms. The study aims to find out if the medicine tenecteplase helps recovery when given after this 4.5-hour window, compared to standard medical care. Tenecteplase is already used within 4.5 hours after stroke onset, but this study tests its effect when given later. Participants are randomly assigned to one of two groups one receives a single injection of tenecteplase into a vein, and the other receives the usual standard treatment. Both groups have an equal chance of receiving either treatment. The study lasts about three months, starting with approximately one week of hospital stay. During the study, participants have seven clinical examinations or visits, with the final two visits conducted remotely from home to allow for easier participation. Throughout the study, doctors regularly assess participants recovery using a scale that measures disability and dependence in daily activities. They also monitor overall health and record any side effects. The main outcome measured is the level of recovery 90 days after treatment, comparing the two groups. This includes neurological improvement, bleeding events, and survival over the study period.

Researchers are evaluating the addition of oral acetazolamide to intravenous furosemide to treat congestion in patients with Acute Decompensated Heart Failure ADHF. This study is based on previous findings from the ADVOR trial and aims to see if oral acetazolamide can increase the success of decongestion, increase urine output, affect NT pro BNP levels, and assess the safety of this combination. The trial is conducted in single hospitals in Indonesia where intravenous acetazolamide is unavailable. This is a randomized, double-blind study with two treatment groups. One group receives intravenous furosemide plus oral acetazolamide at a dose of 250 mg every 12 hours for up to three days, while the other group receives intravenous furosemide plus a placebo orally at the same schedule. The study expects that the combination therapy group will experience faster fluid reduction, leading to shorter treatment duration and less total diuretic use. Participants diagnosed with ADHF who meet eligibility criteria will be randomized and monitored for at least three days to evaluate successful decongestion. Researchers will assess urinary output, NT pro BNP levels, renal function, and length of hospital stay up to 30 days. Kidney function will be monitored every 48 hours or as needed for up to 90 days, and urinary output is tracked until discharge and up to seven days after. The study includes safety monitoring and follow-up to evaluate overall treatment effects.

Researchers are evaluating the real-world effectiveness and safety of Nebilet4 nebivolol in adults with hypertension across seven Asian countries. This multinational, multicenter, observational, and prospective study aims to assess blood pressure changes, treatment adherence, quality of life, prescription patterns, and cardiovascular outcomes over up to three years. The study also compares Nebilet4 used alone versus in combination therapy and investigates the relationship between home and office blood pressure measurements. Participants include about 5,000 adults newly diagnosed with or having uncontrolled hypertension who have recently started Nebilet4 or been on it no more than two weeks. Patients are followed regularly for 12, 24, and 36 months, with blood pressure measured at each visit and home readings encouraged. The study collects data on medication dosing and frequency, adherence, and cardiovascular risk factors, while monitoring major adverse cardiac events such as heart attack, stroke, and cardiovascular death. During the study, participants complete questionnaires to assess quality of life and medication adherence every few months. Data are recorded through an electronic system ensuring consistency across sites. Researchers evaluate changes in systolic and diastolic blood pressure and the proportion achieving target blood pressure goals. Safety and any adverse events are documented, with follow-up visits extending up to three years to provide insights into the long-term management of hypertension with Nebilet4.

Researchers are studying the effects of synbiotic supplementation on patients with Metabolic Dysfunction-Associated Fatty Liver Disease MAFLD, a type of fatty liver condition linked to metabolic issues like obesity and diabetes. This research aims to see if synbiotics can change metabolic profiles, insulin levels, inflammatory marker TNF-alpha, and gut microbiota in these patients. The study is designed as a randomized controlled trial to analyze these effects in adults aged 25 to 55 years. Participants are divided into two groups one receives RILLUS, a synbiotic supplement containing specific probiotic bacteria and prebiotic fibers, while the other receives a placebo that looks similar but lacks the live bacteria. Both groups will take two tablets daily for 12 weeks. Hospital visits for control and follow-up occur every 28 days over about four months. Participants will also keep logs to track supplement intake and food consumption. Throughout the study, participants will undergo various assessments including blood tests for hematology, metabolic profiles, insulin, TNF-alpha, and C-reactive protein at three months. Gut microbiota diversity will be evaluated at four months. The researchers will monitor compliance and collect data to understand how synbiotic treatment may influence these health markers. The total study duration for each participant is about four months, including supplementation and follow-up periods.

Researchers are evaluating the relationship between a visual echocardiographic scoring system, called the visual mitral and tricuspid VMT score, and clinical outcomes in patients with acute decompensated heart failure. The study uses secondary data collected from hospital registries, including demographic information, clinical presentations, laboratory tests, and echocardiographic results from patients diagnosed with this condition. The data analysis is performed using IBM SPSS Statistics v26. This is an observational study that does not involve experimental treatments. Instead, it reviews existing medical records and echocardiographic machine databases to gather information on patients hospitalized with acute decompensated heart failure. The study focuses on clinical outcomes such as mortality during hospitalization, length of stay in the intensive cardiac care unit ICCU, and urine output. Participants are patients aged 18 to 70 years with a history of heart failure with reduced ejection fraction LVEF <40%. Researchers analyze data collected during hospitalization lasting up to one week. The study measures outcomes including death during hospitalization, ICCU length of stay, and urine output. No interventions or treatments are administered as part of this study, and participation involves review of existing patient data only.

Researchers are evaluating the effects of low-level tragus stimulation LLTS on heart function in patients who have experienced ST-segment Elevation Myocardial Infarction STEMI and are undergoing primary percutaneous coronary intervention PPCI. This study aims to understand if LLTS can improve measures such as left ventricular ejection fraction, wall motion score index, and diastolic function compared to a sham control. The safety of LLTS in this setting is also being assessed. Participants will be randomly assigned to one of two groups the treatment group receiving LLTS via the Parasym device on the left tragus for 60 minutes, or the sham control group where the Parasym device is implanted without active stimulation for the same duration. Both groups will undergo transthoracic echocardiography examinations before and after PPCI to assess heart function. During the study, participants will have echocardiographic measurements taken before PPCI, one day after PPCI, and 30 days after PPCI to monitor changes in left ventricular ejection fraction, wall motion score index, and diastolic function. The study will last through these time points to evaluate both the effect and safety of LLTS treatment in STEMI patients.

Researchers are evaluating the prognostic value of the anion gap in predicting major adverse cardiovascular events among patients diagnosed with ST-segment elevation myocardial infarction STEMI. This observational study collects secondary data from hospital records of inpatients who underwent primary percutaneous coronary intervention PPCI for STEMI. The data includes demographic information, clinical presentation, laboratory results, and angiography findings, which are analyzed using IBM SPSS Statistics v26. The study involves measuring the anion gap through blood examination before PPCI as a diagnostic test. Patients are grouped based on whether they suffered major adverse cardiovascular events MACE after the procedure. The research focuses on the relationship between initial anion gap levels and subsequent cardiovascular complications during hospitalization. Participants information is gathered from hospital registries by reviewing medical records. Researchers track the occurrence of MACE and other outcomes such as mortality, reinfarction, stroke, lethal arrhythmia, acute lung oedema, and cardiogenic shock during the hospital stay, up to one week. The study helps to understand how anion gap values relate to these serious events in STEMI patients treated with PPCI.

Researchers are evaluating the prognostic value of the anion gap in predicting mortality among patients diagnosed with acute pulmonary embolism. This observational study uses secondary data collected from hospital records, including demographic details, clinical presentation, laboratory results, and CT scan findings. The analysis aims to understand how the anion gap relates to patient outcomes during hospitalization. The study involves reviewing medical records of patients diagnosed with acute pulmonary embolism confirmed by CT scan. The main focus is on patients who survived hospitalization, while data from those who did not survive are also analyzed using the anion gap as a diagnostic measure. Researchers use statistical software to analyze the collected information. Participants involvement includes retrospective data collection from hospital registries without direct intervention. The primary outcome measured is in-hospital mortality during the hospitalization period, up to one week. The study provides insights based on existing patient data without requiring additional visits or procedures, and it is sponsored by Universitas Diponegoro.

Researchers are evaluating a new Morphology-Voltage-P-wave Score MVP Score to help diagnose left ventricular diastolic dysfunction in people with hypertension. This observational study collects detailed data including demographics, clinical signs, laboratory tests, and heart ultrasound echocardiography results to validate the usefulness of the MVP Score in identifying heart dysfunction related to high blood pressure. Participants will have their 12-lead electrocardiogram ECG reviewed to calculate the MVP Score, which will then be compared with results from transthoracic echocardiography assessing heart function. The study groups include patients with and without left ventricular diastolic dysfunction, based on these assessments. During the study, investigators will gather information from medical records and perform ECG and echocardiography evaluations. They will analyze the data using statistical software to confirm the MVP Scores accuracy in diagnosing diastolic dysfunction. The main outcome measured is the presence of diastolic dysfunction within one week of assessment. Participation involves one-time diagnostic tests and data collection with no treatment interventions.